Active Biotech announces new direction

PRESS RELEASE

Active Biotech AB - Year-end report January - December 2019

PRESS RELEASE

New preclinical data on naptumomab estafenatox will be presented at the Society for Immunotherapy of Cancer’s 34th Annual Meeting

POSTER

Active Biotech and NeoTX today announce first patient dosed in the Phase 1b trial of naptumomab estafenatox in combination with durvalumab in solid tumors

PRESS RELEASE

NAPTUMOMAB Tumor Targeting Immunotherapy

Naptumomab: Clinical Development

Develops Novel Treatments for Cancer and Inflammatory Diseases

ABOUT US

An Experienced Team — Building Solid Partnerships

MANAGEMENT

Novel immunomodulatory treatments for patients with cancer or inflammatory diseases

Active Biotech focuses on the research and development of pharmaceuticals in therapeutic areas in which the immune system is of central importance. The project portfolio comprises therapy developed for the treatment of cancer and inflammatory diseases.

Diseases where the immune system is of central importance